Publikationsverzeichnis (Auswahl):
Selberherr A, Mari M, Klinger M, Burghuber C, Eilenberg W, Gollackner B, Neumayer C, Domenig C. Left Renal Vein Division for Juxtarenal Aortic Exposure:Influence on Renal Function and Role of the Communicating Lumbar Vein.
World JSurg. 2022 Jun;46(6):1493-1499.
Eilenberg W, Klopf J, Domenig CM, Klinger M, Wolf F, Gollackner B, Nanobachvili J, Neumayer C. The Femoral Vein as a Long-Term Aorto-Iliac Graft for Aortic Infection and Aortitis. World J Surg. 2022 May;46(5):1235-1242.
Jabłońska A, Zagrapan B, Paradowska E, Neumayer C, Eilenberg W, Brostjan C, Klinger M, Nanobachvili J, Huk I. Abdominal aortic aneurysm and virus infection: A potential causative role for cytomegalovirus infection? J Med Virol. 2021
Aug;93(8):5017-5024.
Jabłońska A, Zagrapan B, Neumayer C, Eilenberg W, Scheuba A, Brostjan C, Demyanets S, Klinger M, Nanobachvili J, Huk I. Polymorphisms in the IL-6 and TNF-α gene are associated with an increased risk of abdominal aortic aneurysm.
Int J Cardiol. 2021 Apr 15;329:192-197.
Eilenberg W, Schwarz M, Schoder M, Klinger M, Kinstner C, Nanobachvili J, Huk I, Neumayer C, Heinze G, Domenig CM. Inverse probability of treatment analysis of open vs endovascular repair in ruptured infrarenal aortic aneurysm - Cohort study. Int J Surg. 2020 Aug;80:218-224.
Jabłońska A, Zagrapan B, Neumayer C, Klinger M, Eilenberg W, Nanobachvili J, Paradowska E, Brostjan C, Huk I. TLR2 2029C/T and TLR3 1377C/T and -7C/A Polymorphisms Are Associated with the Occurrence of Abdominal Aortic Aneurysm. J Immunol. (2020) 204: 2900-2909
Jabłońska A, Neumayer C, Bolliger M, Burghuber C, Klinger M, Demyanets S, Nanobachvili J, Huk I. Insight into the expression of toll-like receptors 2 and 4 in patients with abdominal aortic aneurysm. Mol Biol Rep. (2020) 47: 2685-269
Jabłońska A, Neumayer C, Bolliger M, Gollackner B, Klinger M, Paradowska E, Nanobachvili J, Huk I. Analysis of host Toll-like receptor 3 and RIG-I-like receptor gene expression in patients with abdominal aortic aneurysm. J Vasc Surg. (2018) 68: 39S-46S
Eilenberg W, Stojkovic S, Kaider A, Kozakowski N, Domenig CM, Burghuber C, Nanobachvili J, Huber K, Klinger M, Neumayer C, Huk I, Wojta J, Demyanets S. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med. (2017) 56: 147-156
Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Gröger M, Klinger M, Wojta J, Neumayer C, Huk I, Demyanets S. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In Vitro. Eur J Vasc Endovasc Surg. (2016) 51: 623-31.
Piechota-Polanczyk A, Demyanets S, Mittlboeck M, Hofmann M, Domenig CM, Neumayer C, Wojta J, Klinger M, Nanobachvili J, Huk I. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue. Eur J Vasc Endovasc Surg. (2015) 49: 549-55.
Piechota-Polanczyk A, Demyanets S, Nykonenko O, Huk I, Mittlboeck M, Domenig CM, Neumayer C, Wojta J, Nanobachvili J, Klinger M. Decreased tissue levels of cyclophilin A, a cyclosporine a target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. (2013) 45: 682-8.
Piechota-Polanczyk A, Goraca A, Demyanets S, Mittlboeck M, Domenig C, Neumayer C, Wojta J, Nanobachvili J, Huk I, Klinger M. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-κB. Eur J Vasc Endovasc Surg. (2012) 44 :133-138
Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, Gruenberger T. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. (2011) 18: 421-30
Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. (2010) 17: 2059-65.
Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg. (2010) 252: 124-30.
Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. (2009) 35: 515-20
Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.
Ann Surg Oncol. (2008) 15: 2787-94.
Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. (2010) 17: 2059-65.
Kandutsch S, Klinger M, Hacker S , Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol (2008) 34: 11231-6
Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, Roth G, Hoetzenecker W, Lichtenauer M, Klinger M, Krenn CG, Ankersmit JH. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration Clin Lab Anal (2007) 21: 277-81.
Farhan H, Schuster C, Klinger M, Weisz E, Waxenecker G, Schuster M, Sexl V, Mudde GC, Freissmuth M, Kircheis R. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther. (2006) 319: 1459-66
Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.J Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J. Natl Cancer Inst. (2005) 97: 1663-70.
Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E.J Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. Immunol. (2004) 173: 394-401. 4
Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. (2004) 64: 1087-93.
Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology. (2003) 28: 1317-27.
Klinger M, Kuhn M, Just H, Stefan E, Palmer T, Freissmuth M, Nanoff C. Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. Naunyn Schmiedebergs Arch Pharmacol. (2002) 366: 287-98.
Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V. MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem. (2002) 277: 32490-7.
Seidel MG, Klinger M, Freissmuth M, Höller C. Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. J Biol Chem. (1999) 274: 25833-41.
Klinger M, Bofill-Cardona E, Mayer B, Nanoff C, Freissmuth M, Hohenegger M. Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochem J. (2001) 355: 827-33.
Klinger M, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J, Hohenegger M. Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site. Mol Pharmacol. (1999) 55: 462-72.
Übersichtsarbeiten:
Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. (2002) 14: 99-108.
Buchbeiträge/Patente:
M. Klinger, M. G. Seidel, C. Höller, M. Platzer and M. Freissmuth. Activation of MAP Kinase by the A2A-Adenosine Receptor. Molecular Mechanisms of Signal Transduction. J.L. Bos, ed. (NATO Science Series Press, Amsterdam, ISBN 1 58603 016 7)
Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures, Juni 2004 PCT/EP2003/0069 12
